Company intelligence / Profile preview

AbbraTech

Branford, Connecticut, United Statesabbratech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

AbbraTech has demonstrated the ability to generate high-affinity, highly specific recombinant antibodies against difficult-to-target epitopes using its proprietary Epivolve platform. The company is advancing internal programs in infectious diseases and immuno-oncology and has received NIH funding for some projects. No published late-stage clinical results as of now.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Recombinant antibodiesMonoclonal antibodies (mAbs)
Industry: Biotech

Partnerships

Collaborations with biotechnology and pharmaceutical companies for custom therapeutic antibody discovery using Epivolve platform.Academic partnerships mentioned but not specified by institution or partner names.

Beyond the preview

Go deeper on AbbraTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbbraTech.

Explore the full profile